Estimated global sales of neurotoxin for therapeutic use.1
Cervical Dystonia
Not actual patients.
Revance’s therapeutic pipeline seeks to bring innovation to multiple indications in muscle movement and pain disorders.
DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA.
Therapeutics
FACTS, FIGURES, & TRENDS
Approved therapeutic indications for botulinum toxin Type A in the U.S. and hundreds of potential indications.1,2
Ongoing clinical trials for therapeutic indications of DaxibotulinumtoxinA for Injection.3,4
DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA.
Daring to Make a Difference in Therapeutics
Our investigational neuromodulator product DaxibotulinumtoxinA for Injection is being evaluated in therapeutic indications, including cervical dystonia (Phase 3) and upper limb spasticity (Phase 2) and has been evaluated in plantar fasciitis (Phase 2).
For the latest information regarding our clinical development programs, please see our public filings with the Securities and Exchange Commissions or visit www.clinicaltrials.gov.
Not an actual patient.
Cervical Dystonia
Positive topline results from Revance's pivotal ASPEN-1 Phase 3 clinical trial evaluating DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia, a debilitating neurologic disorder affecting the neck muscles, were announced in October 2020. The results demonstrate a potential advancement in the treatment paradigm for patients affected by cervical dystonia. The ASPEN-OLS Phase 3 open-label, long-term safety study results are expected in 2021.
Learn More
Adult Upper Limb Spasticity
In February 2021, Revance announced positive topline Phase 2 data supporting advancement of DaxibotulinumtoxinA for Injection for the treatment of upper limb spasticity. Adult upper limb spasticity is a neurologic condition that affects movement in the arms and/or hands and occurs most commonly after a stroke or brain injury.
Learn More
Plantar Fasciitis
Plantar fasciitis is characterized by inflammation and sharp, constant pain in the heel that can become incapacitating. Results from the Phase 2 placebo-controlled clinical trial of DaxibotulinumtoxinA for Injection for the management of plantar fasciitis were announced in November 2020. Revance plans to analyze the data further for additional insights, however our primary focus will be on neuromodulator indications, where the market and path to approval are well established.
Learn MoreMigraine
Revance is also considering studying DaxibotulinumtoxinA for Injection for migraines. Potential timing of clinical studies is currently being evaluated.
Therapeutics Clinical Program Update
- PRECLINICAL
- PHASE 1
- PHASE 2
- PHASE 3
DaxibotulinumtoxinA for Injection — Therapeutics
PHASE 3 COMPLETE
Plantar Fasciitis
IN
PHASE 2
Upper Limb Spasticity
IN
PHASE 2
ASPEN-OLS Readout in 2021
*Reported results in Nov 2020
Readout in Early 2021
*Revance is continuing to evaluate next steps in plantar fasciitis
Publications
DaxibotulinumtoxinA for Injection is an investigational product. It is currently undergoing clinical studies for both therapeutic and aesthetic indications.
References
-
2019 (E) based on Decision Resources Group Therapeutic Botulinum Toxin Market Analysis Global 2019, November 2018
-
Time Magazine, January 16, 2017, How BOTOX Became the Drug That’s Treating Everything. Available at: https://time.com/4623409/botox-drug-treating-everything/. Accessed April 2020
-
Clinicaltrials.gov. US National Library of Medicine. Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity (JUNIPER). Available at: https://clinicaltrials.gov/ct2/show/NCT03821402. Accessed July 2019.
Career Opportunities
Do you have what it takes to join our team? Check out our Careers page and find out.
Learn More